15 June 2016 - Glassia is the only FDA approved alfa-1 antitrypsin (human) augmentation treatment that patients can self-infuse at home.

 Shire and Kamada today announced that the U.S. FDA has approved an expanded label for Glassia [alfa-1 proteinase Inhibitor (human)], marking the first treatment for adult patients with emphysema due to severe alfa-1 antitrypsin (AAT) deficiency that can be self-infused at home after appropriate training.

Patients with AAT deficiency have low or undetectable levels of a protein called alfa-1 antitrypsin or AAT, which helps protect lung tissue from damaging enzymes that are released by white blood cells.1 AAT deficiency can result in early onset emphysema. Treatment with Glassia replaces the missing or deficient AAT protein in the blood and lungs.

For more details, go to: https://www.shire.com/newsroom/2016/june/15a-06-2016-shire-and-kamada-announce-fda-approval